MedTrace Logo

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

NCT03235050 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 834

Last updated 2020-08-17

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

MEDI0382 low dose

Pharmaceutical form: solution Route of administration: subcutaneous

DRUG

MEDI0382 mid dose

Pharmaceutical form: solution Route of administration: subcutaneous

DRUG

MEDI0382 high dose

Pharmaceutical form: solution Route of administration: subcutaneous

DRUG

Placebo

Pharmaceutical form: solution Route of administration: subcutaneous

DRUG

Liraglutide

Pharmaceutical form: solution Route of administration: subcutaneous

Sponsors & Collaborators

  • MedImmune LLC

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-02
Primary Completion
2018-05-03
Completion
2019-06-14
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • Germany
  • Mexico
  • Russia
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03235050 on ClinicalTrials.gov